Status:
COMPLETED
Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery
Lead Sponsor:
Glaukos Corporation
Conditions:
Primary Open-angle Glaucoma
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
Evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 using the G2-M-IS injector system in conjunction with cataract surgery vs. cataract surgery only, in subjects...
Detailed Description
The purpose of this study is to evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 using the G2-M-IS injector system in conjunction with cataract surgery, compa...
Eligibility Criteria
Inclusion
- Mild to moderate open-angle glaucoma
- Characteristics consistent with mild/moderate glaucoma
- Use of one (1) to three (3) medications at time of screening exam
Exclusion
- Pigmentary or pseudoexfoliative glaucoma
- Prior incisional glaucoma surgery
Key Trial Info
Start Date :
January 16 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2018
Estimated Enrollment :
505 Patients enrolled
Trial Details
Trial ID
NCT01461291
Start Date
January 16 2012
End Date
October 1 2018
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Centers of Racine and Kenosha
Racine, Wisconsin, United States, 53405